Site Editors

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP

Advertisement
Advertisement

Venetoclax Plus Bortezomib and Dexamethasone in Resistant Myeloma: Final Results From BELLINI Trial

By: Joseph Fanelli
Posted: Friday, March 11, 2022

According to findings presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 84), using venetoclax in combination with bortezomib and dexamethasone significantly improved progression-free survival but also resulted in increased mortality when compared with a placebo in patients with relapsed or refractory multiple myeloma. Philippe Moreau, MD, PhD, of the University Hospital Hôtel-Dieu, Nantes, France, and colleagues concluded that findings from this phase III BELLINI study were consistent with a previous analysis and the oral BCL2 inhibitor venetoclax demonstrated the greatest improvement in patients with high BCL2 expression.

In this randomized, double-blind, multicenter study, the authors enrolled 291 patients with relapsed or refractory multiple myeloma. The patients received bortezomib and dexamethasone with either venetoclax (194 patients) or a placebo (97 patients). At the final overall survival analysis, 33 patients were still receiving treatment (28 with venetoclax and 5 with a placebo).

After a median follow-up of 45.6 months, 78 patients treated with venetoclax died (40%), compared with 36 in the placebo cohort (37%). The median progression-free survival was 23.4 months for those treated with venetoclax and 11.4 months for those who received a placebo. For patients with t(11;14) translocation, the median progression-free survival was 36.8 months in the venetoclax cohort and 9.3 months in the placebo group. Patients with high BCL2 expression had a median progression-free survival of 30.1 months when treated with venetoclax and 9.9 months when treated with a placebo. The median overall survival was not reached in either group of patients.

Serious adverse events occurred in 57% of patients treated with venetoclax and 55% of placebo-treated patients, with serious infections and infestations occurring in 35% and 29% of patients, respectively. In total, 26% of patients who received venetoclax experienced adverse events that led to discontinuation of treatment, compared with 11% of patients who received a placebo. Adverse events resulted in 12 deaths among those treated with venetoclax and 1 death in the placebo group.

Disclosure: For full disclosure of the study authors, visit ash.com.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.